Emergent BioSolutions to Release Third Quarter 2010 Financial Results and Conduct a Conference Call on November 4, 2010
ROCKVILLE, Md., Oct 13, 2010 — Emergent BioSolutions Inc. (NYSE: EBS) announced today it will report financial results for third quarter 2010 on Thursday November 4, 2010, after market close. Company management will host a conference call at 5:00 pm Eastern on November 4, 2010 to discuss the financial results for [...]
October 23, 2010
Tags: Anthrax, Anthrax vaccines, Chief executive officer, Conference call, Emergent BioSolutions, Food and Drug Administration, fuad el-hibri, New York Stock Exchange Posted in: Anthrax vaccines, Biosolutions, Biothrax, Emergent BioSolutions, fuad el-hibri 
No Comments
Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares
CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share.
EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the body\’s [...]
August 14, 2009
Tags: Anthrax, Anthrax vaccines, Emergent BioSolutions, Health, Infectious disease, Public health, U.S. Food and Drug Administration, Vaccine Posted in: Board of Directors, CEO, Emergent BioSolutions, Shareholders, fuad el-hibri No Comments
U.S. Government To Purchase Additional 14.5 Million Doses Of Biothrax® Under New Contract Valued At Up To $404 Million
New contract extends USG’s commitment to purchase BioThrax through 3Q 2011 and is a follow-on to the existing 2007, $448 million contract
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has signed a new, multi-year, firm fixed price contract with the U.S. Department of Health and Human Services (HHS) to supply an additional 14.5 million [...]
July 13, 2009
Tags: Anthrax, Anthrax vaccines, Emergent BioSolutions, Private Securities Litigation Reform Act, Strategic National Stockpile, U.S. Food and Drug Administration, U.S. Government, United States Department of Health and Human Services, United States. Posted in: Uncategorized No Comments
Emergent Biosolutions Acquires Monoclonal Anthrax Product Candidate
Acquisition represents important addition to company’s portfolio of anthrax countermeasures
Emergent BioSolutions Inc. (NYSE: EBS) announced that today it completed the acquisition of a group of anthrax monoclonal antibodies from AVANIR Pharmaceuticals (NASDAQ:AVNR), including Avanir’s lead product candidate, AVP-21D9.
AVP-21D9 is a human monoclonal antibody product candidate that is being developed as an intravenous treatment for patients [...]
July 13, 2009
Tags: Anthrax, Clinical trial, Infectious disease, Monoclonal antibodies, National Institute of Allergy and Infectious Diseases, NIAID, U.S. Food and Drug Administration, United States. Posted in: Uncategorized No Comments